AGL 8.30 Decreased By ▼ -0.03 (-0.36%)
ANL 10.95 Increased By ▲ 0.25 (2.34%)
AVN 79.70 Increased By ▲ 1.51 (1.93%)
BOP 5.75 Increased By ▲ 0.18 (3.23%)
CNERGY 5.64 Increased By ▲ 0.26 (4.83%)
EFERT 79.36 Increased By ▲ 0.71 (0.9%)
EPCL 67.48 Decreased By ▼ -0.31 (-0.46%)
FCCL 14.89 Increased By ▲ 0.39 (2.69%)
FFL 6.70 Increased By ▲ 0.10 (1.52%)
FLYNG 7.16 Increased By ▲ 0.13 (1.85%)
GGGL 11.60 Increased By ▲ 0.26 (2.29%)
GGL 17.51 Increased By ▲ 0.27 (1.57%)
GTECH 8.35 Increased By ▲ 0.05 (0.6%)
HUMNL 7.17 Increased By ▲ 0.11 (1.56%)
KEL 3.14 Increased By ▲ 0.06 (1.95%)
LOTCHEM 35.20 Increased By ▲ 2.33 (7.09%)
MLCF 28.35 Increased By ▲ 0.05 (0.18%)
OGDC 87.70 Increased By ▲ 3.15 (3.73%)
PAEL 16.63 Increased By ▲ 0.18 (1.09%)
PIBTL 6.05 Increased By ▲ 0.20 (3.42%)
PRL 19.46 Increased By ▲ 1.34 (7.4%)
SILK 1.14 No Change ▼ 0.00 (0%)
TELE 11.41 Increased By ▲ 0.31 (2.79%)
TPL 9.20 Increased By ▲ 0.20 (2.22%)
TPLP 20.25 Increased By ▲ 0.37 (1.86%)
TREET 27.10 Increased By ▲ 0.48 (1.8%)
TRG 96.20 Increased By ▲ 1.70 (1.8%)
UNITY 20.85 Increased By ▲ 0.48 (2.36%)
WAVES 13.90 Increased By ▲ 0.27 (1.98%)
WTL 1.34 Increased By ▲ 0.03 (2.29%)
BR100 4,275 Increased By 67 (1.59%)
BR30 15,794 Increased By 348.3 (2.26%)
KSE100 42,872 Increased By 628.4 (1.49%)
KSE30 16,219 Increased By 247.6 (1.55%)
World

Novavax Covid vaccine highly effective against severe Covid: company

  • The results announced Thursday were from final analyses, following interim results that were announced in late January.
Published March 12, 2021

WASHINGTON: US biotech firm Novavax's Covid-19 vaccine was shown to be 100 percent protective against severe cases of the disease, including hospitalization and death, the company said Thursday following trials.

But its efficacy against the South African variant fell markedly when including mild and moderate cases, results showed.

The results announced Thursday were from final analyses, following interim results that were announced in late January.

In a Phase 3 trial in Britain that included 15,000 participants aged 18-84, including 27 percent over the age of 65, efficacy against mild, moderate and severe Covid was 96.4 percent against the original strain.

This fell to 89.7 when including people infected with the B.1.1.7 variant, which has been shown to be more transmissible and cause more severe disease.

In South Africa, a smaller Phase 2b trial of some 2,600 people found it was 48.6 percent effective, though the figure rose to 55.4 percent among HIV-negative volunteers.

Across both trials, the vaccine known as NVX-CoV2373 demonstrated 100 percent protection against severe disease.

Unlike the Pfizer, Moderna and AstraZeneca vaccines, which deliver the genetic instructions that make human cells create a key protein of the virus, the Novavax shot injects synthetic versions of these proteins directly into the body to evoke an immune response.

The Maryland-based company has said it hopes to file for British approval of its Covid-19 vaccine at the start of the second quarter of 2021, and to do the same soon after in the United States.

Comments

Comments are closed.